The 3-year clinical results of NOBORI 2 study show consistently low occurrence of clinical events throughout the trial.
Acute Myocardial infarction (AMI), commonly known as a heart attack, is the irreversible necrosis of heart muscle secondary to prolonged ischemia due to lack of oxygen supply. Most often it is caused by plaque rupture with thrombus formation in a coronary vessel, resulting in an acute reduction of blood supply to a portion of the myocardium. There is an indisputable scientific evidence that percutaneous myocardial revascularisation in patients with acute forms of coronary artery disease is life saving and limits potential disabilities. Hence it has been recommended in the latest AMI management guidelines.
Terumo has long term commitment to optimizing the treatment of Acute Myocardial Infarction with strong scientific and educational support, exceptional product portfolio and exciting new technology.
Radial access solutions
for reduced risk of bleeding
for thrombus aspiration
Patient-friendly compression of radial artery
NOBORI 2 – AMI / Presented at PCR May 20, 2011, F. Fath-Ordoubadi
Women have a higher risk of adverse outcomes after percutaneous coronary intervention than men. Nevertheless no differences in 3 year outcomes were observed between men and women treated for ACS with Nobori® DES.
NOBORI 2 – ACS/Gender / Presented at PCR May 18, 2012, F. Fath-Ordoubadi
TROFI study / Presented at TCT November 7, 2011, P. W. Serruys
Fast, Effective and Safe: making the right choices in STEMI - Presented at PCR May 17, 2012, M. Valgimigli
For further information, please contact your local Terumo representative.
Site map |
Legal and Privacy Information
© Terumo Europe N.V. | Webdesign: Mediaction